By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Eisai Inc. 

100 Tice Boulevard

Woodcliff Lake  New Jersey  07677  U.S.A.
Phone: 201-692-1100 Fax: 201-692-1804

Headquartered in Woodcliff Lake, New Jersey, Eisai Inc. was established in 1995 and is ranked among the top-20 U.S. pharmaceutical companies (based on retail sales). The company began marketing its first product in the United States in 1997 and has rapidly grown to become a fully integrated pharmaceutical business. Eisai’s areas of commercial focus include neurology, gastrointestinal disorders and oncology/critical care. The company serves as the U.S. pharmaceutical operation of Eisai Co., Ltd., a research-based human health care (hhc) company that discovers, develops and markets products throughout the world.

Eisai has a global product creation organization that includes U.S.-based R&D facilities in Maryland, Massachusetts, New Jersey, North Carolina and Pennsylvania as well as manufacturing facilities in Maryland and North Carolina. The company’s areas of R&D focus include neuroscience; oncology; vascular, inflammatory and immunological reaction; and antibody-based programs. For more information about Eisai, please visit

For more information about Eisai, please visit

Key Statistics

Ownership: Subsidiary

Web Site: Eisai Inc.
Employees: Approximately 2,600
Symbol: ESALF.PK


Company News
FDA Approves Eisai Inc. (ESALF.PK)'s LENVIMA (Lenvatinib) For The Treatment Of Patients With Advanced Renal Cell Carcinoma In Combination With Everolimus Following Prior Anti-Angiogenic Therapy 5/16/2016 6:04:35 AM
Dr. Avinash Desai Appointed Vice President, Americas Oncology Medical Affairs, Oncology Business Group At Eisai Inc. (ESALF.PK) 4/20/2016 6:45:24 AM
Eisai Inc. (ESALF.PK) Release: Paul Hawthorne Appointed Senior Vice President, U.S. Commercial, Neurology Business Group At Eisai Inc. (ESALF.PK) 4/6/2016 6:29:27 AM
Data On Eisai Inc. (ESALF.PK)'s Halaven (eribulin mesylate) Injection In Advanced Liposarcoma Published In The Lancet 2/11/2016 6:31:52 AM
Eisai Inc. (ESALF.PK)'s Lenvatinib Receives FDA Priority Review For The Potential Treatment Of Advanced Renal Cell Carcinoma In Combination With Everolimus 1/18/2016 10:50:40 AM
Eisai Inc. (ESALF.PK) Presents Data On Perampanel And First And Largest U.S. Study On Caregiver Burden In Epilepsy At The 69th Annual American Epilepsy Society Meeting 12/2/2015 7:01:03 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce Completion Of Enrollment In BELVIQ (lorcaserin HCI) CAMELLIA-TIMI 61 Study 12/1/2015 6:47:44 AM
Helsinn Group And Eisai Inc. (ESALF.PK) Announce Inclusion Of AKYNZEO (netupitant/palonosetron) In ASCO Antiemetics Guideline Update 11/13/2015 7:29:56 AM
Eisai Inc. (ESALF.PK) Signs Research Collaboration Agreement With The Paoli Calmettes Institute 11/4/2015 6:27:02 AM
Eisai Inc. (ESALF.PK) And Arena (ARNA) Announce Presentation Of Lorcaserin Hcl Data At 2015 Annual Obesity Week Meeting 11/2/2015 6:43:51 AM